

- Irvine AD (2007) Fleshing out filaggrin phenotypes. *J Invest Dermatol* 127:504-507
- Kirov G, Jones I, McCandless F, Craddock N, Owen MJ (1999) Family-based association studies of bipolar disorder with candidate genes involved in dopamine neurotransmission: DBH, DAT1, COMT, DRD2, DRD3 and DRD5. *Mol Psychiatry* 4:558-565
- Larsen FS, Holm NV, Henningsen K (1986) Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. *J Am Acad Dermatol* 15:487-494
- Lee YA, Wahn U, Kehrt R, Tarani L, Businco L, Gustafsson D, Andersson F, Oranje AP, Wolkertstorfer A, v Berg A, Hoffmann U, Kuster W, Wienker T, Ruschendorf F, Reis A (2000) A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. *Nat Genet* 26:470-473
- Levy RM, Gelfand JM, Yan AC (2003) The epidemiology of atopic dermatitis. *Clin Dermatol* 21:109-115
- Listwan P, Rothnagel JA (2004) Keratin bundling proteins. *Methods Cell Biol* 78:817-827
- Marenholz I, Nickel R, Ruschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, Gruber C, Lau S, Worm M, Keil T, Kurek M, Zaluga E, Wahn U, Lee YA (2006) Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. *J Allergy Clin Immunol* 118:866-871
- Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A (1996) Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. *J Invest Dermatol* 106:989-992
- Morar N, Cookson WO, Harper JI, Moffatt MF (2007) Filaggrin mutations in children with severe atopic dermatitis. *J Invest Dermatol* 127:1667-1672
- Morar N, Willis-Owen SA, Moffatt MF, Cookson WO (2006) The genetics of atopic dermatitis. *J Allergy Clin Immunol* 118:24-34; quiz 35-26
- Nomura T, Sandilands A, Akiyama M, Liao H, Evans AT, Sakai K, Ota M, Sugiura H, Yamamoto K, Sato H, Palmer CN, Smith FJ, McLean WH, Shimizu H (2007) Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. *J Allergy Clin Immunol* 119:434-440
- Nystad W, Roysamb E, Magnus P, Tambs K, Harris JR (2005) A comparison of genetic and environmental variance structures for asthma, hay fever and eczema with symptoms of the same diseases: a study of Norwegian twins. *Int J Epidemiol* 34:1302-1309
- Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A,

- Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* 38:441-446
- Ruether A, Stoll M, Schwarz T, Schreiber S, Folster-Holst R (2006) Filaggrin loss-of-function variant contributes to atopic dermatitis risk in the population of Northern Germany. *Br J Dermatol* 155:1093-1094
- Sandilands A, O'Regan GM, Liao H, Zhao Y, Terron-Kwiatkowski A, Watson RM, Cassidy AJ, Goudie DR, Smith FJ, McLean WH, Irvine AD (2006) Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. *J Invest Dermatol* 126:1770-1775
- Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, Carrick T, Evans AT, Liao H, Zhao Y, Campbell LE, Schmuth M, Gruber R, Janecke AR, Elias PM, van Steensel MA, Nagtzaam I, van Geel M, Steijlen PM, Munro CS, Bradley DG, Palmer CN, Smith FJ, McLean WH, Irvine AD (2007) Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet* 39:650-654
- Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Lewis-Jones S, Arseculeratne G, Munro CS, Sergeant A, O'Regan G, Bale SJ, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WH (2006) Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. *Nat Genet* 38:337-342
- Stemmler S, Parwez Q, Petrasch-Parwez E, Epplen JT, Hoffjan S (2007) Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis. *J Invest Dermatol* 127:722-724
- Sugiura H, Ebise H, Tazawa T, Tanaka K, Sugiura Y, Uehara M, Kikuchi K, Kimura T (2005) Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. *Br J Dermatol* 152:146-149
- Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A, Klopp N, Wagenpfeil S, Zhao Y, Liao H, Lee SP, Palmer CN, Jenneck C, Maintz L, Hagemann T, Behrendt H, Ring J, Nothen MM, McLean WH, Novak N (2006) Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. *J Allergy Clin Immunol* 118:214-219
- Weidinger S, Rodriguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T, Novak N (2007) Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. *J Invest*

Dermatol 127:724-726

Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, Asher I, Beasley R, Bjorksten B, Burr M, Clayton T, Crane J, Ellwood P, Keil U, Lai C, Mallol J, Martinez F, Mitchell E, Montefort S, Pearce N, Shah J, Sibbald B, Strachan D, von Mutius E, Weiland SK (1999) Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. *J Allergy Clin Immunol* 103:125-138

Table1. TDT and PDT analysis of the *FLG* polymorphisms in the Japanese AD families

Polymorphism	SNP	Allele	Allele frequency	T <sup>a</sup>	NT <sup>b</sup>	TDT P value	PDT P value
rs11582620	A/G	A	0.89	41	26	0.066	0.059
rs11586114	A/G	G	0.55	90	78	0.35	0.11
rs1933064	A/G	A	0.85	44	35	0.31	0.24
rs2065958(D3105Y)	A/C	C	0.36	69	92	0.069	0.038
rs3814299(L3970S)	A/G	A	0.63	95	70	0.24	0.38
rs12730241	A/G	G	0.057	21	14	0.051	0.021
3321delA	A/-	del	0.014	4	4	1	1
S2554X	C/G	G	0.021	10	4	0.11	0.16

<sup>a</sup>T: Number of alleles transmitted to affected children

<sup>b</sup>NT: Number of alleles not transmitted to affected children

Table 2. Case-control study for AD in *FLG* polymorphisms

Polymorphism	Population <sup>a</sup>	Genotype count (frequency%)				Genotypic <i>P</i> <sup>b</sup>	Odds ratio (95% CI) <sup>c</sup>	Allelic <i>P</i> <sup>b</sup>
		C/C	C/A	A/A	A/A			
rs2065958	AD	58	156	158	(42.5)	0.94	1.0 (0.8-1.2)	0.84
	only AD	9	25	39	(34.3)	0.14	0.6 (0.4-1.0)	0.068
	IgE>1000IU/L	30	90	90	(42.9)	0.89	1.0 (0.7-1.3)	0.62
	early onset	12	57	43	(50.9)	0.20	1.1 (0.8-1.7)	0.81
	Controls	142	393	380	(41.5)			
rs3814299	AD	2	52	322	(85.7)	0.64	1.1 (0.8-1.6)	0.54
	AD alone	0	12	63	(84.0)	0.46	1.3 (0.7-2.5)	0.57
	IgE>1000IU/L	1	34	176	(83.4)	0.26	1.4 (0.9-2.0)	0.21
	early onset	1	14	97	(86.6)	0.98	1.1 (0.6-1.9)	0.84
	Controls	7	111	804	(87.2)			
3321delA	AD	356	10	0	(2.7)	0.077	2.1 (0.9-4.9)	0.077
	AD alone	71	3	0	(4.1)	0.064	3.2 (0.9-11.5)	0.064
	IgE>1000IU/L	198	9	0	(4.4)	0.0038	3.4 (1.4-8.2)	0.0036
	early onset	103	3	0	(2.8)	0.22	2.2 (0.6-7.9)	0.22
	Controls	902	12	0	(1.3)			
S2554X	AD	365	10	0	(2.7)	0.0012	5.0 (1.7-14.8)	0.0012
	AD alone	71	4	0	(5.3)	0.00024	10.3 (2.7-39.4)	0.00024
	IgE>1000IU/L	207	5	0	(2.3)	0.011	4.4 (1.3-15.5)	0.011
	early onset	110	2	0	(1.8)	0.13	3.3 (0.6-17.4)	0.13
	Controls	918	5	0	(0.5)			
combined (3321delA and S2554X)	AD	355	20	0	(5.3)	0.00073	3.0 (1.5-5.8)	0.00067
	AD alone	67	7	0	(9.5)	0.00047	5.5 (2.2-13.8)	0.00042
	IgE>1000IU/L	198	14	0	(6.6)	0.00015	3.7 (1.8-7.7)	0.00014
	early onset	101	5	0	(4.7)	0.054	2.6 (1.0-7.3)	0.056
	Controls	900	17	0	(1.9)			

<sup>a</sup> AD alone; AD patients without other atopic disease. Early onset; patients whose disease onset was younger than 2 years old.

<sup>b</sup> Genotypic *P* and allelic *P* values were calculated with  $\chi^2$  test in comparison with genotype and allele counts in controls, respectively.

<sup>c</sup> Odds ratio for the wild type homozygote versus minor allele heterozygote and minor allele homozygote. CI, confidence interval.

Table 3. Combined *P* values of *FLG* polymorphisms in families and case-control study

Polymorphism	Genotype count (frequency%)						Genotypic <i>P</i> <sup>a</sup>	Odds ratio (95% CI) <sup>b</sup>	Allelic <i>P</i> <sup>a</sup>
	C/C	C/A	A/A	A/G	G/G	A/-			
rs2065958	AD	65 (13.8)	202 (43.0)	203 (43.2)			0.54	0.92 (0.7-1.1)	0.28
	Controls	161 (15.9)	437 (43.0)	417 (41.1)					
rs12730241	AD	4 (0.8)	60 (12.6)	412 (86.6)			0.91	1.1 (0.8-1.5)	0.69
	Controls	7 (0.7)	124 (12.1)	892 (87.2)					
3323delA	AD	454 (97.4)	12 (2.6)	0 (0)			0.14	1.8 (0.8-3.8)	0.14
	Controls	999 (98.5)	15 (1.5)	0 (0)					
S2554X	AD	459 (96.6)	16 (3.4)	0 (0)			0.000091	5.0 (2.1-12.3)	0.0001
	Controls	1010 (99.3)	7 (0.7)	0 (0)					
combined (3321delA and S2554X)	AD	wild / wild	wild / null	null / null			0.00015	2.9 (1.6-5.1)	0.00017
	Controls	438 (94.0)	28 (6.0)	0 (0)					
		992 (97.8)	22 (2.2)	0 (0)					

<sup>a</sup>Genotypic *P* and allelic *P* values were calculated with  $\chi^2$  test in comparison with genotype and allele counts in controls, respectively.

<sup>b</sup>Odds ratio for the wild type homozygote versus minor allele heterozygote and minor allele homozygote. CI, confidence interval.

# Repeated instillations of *Dermatophagoides farinae* into the airways can induce Th2-dependent airway hyperresponsiveness, eosinophilia and remodeling in mice

## Effect of intratracheal treatment of fluticasone propionate

Keiko Wakahara<sup>a,b</sup>, Hiroyuki Tanaka<sup>a,\*</sup>, Go Takahashi<sup>a</sup>, Mayumi Tamari<sup>c</sup>,  
Reishi Nasu<sup>a</sup>, Tatsuyuki Toyohara<sup>a</sup>, Hirohisa Takano<sup>d</sup>, Saburo Saito<sup>e</sup>,  
Naoki Inagaki<sup>a</sup>, Kaoru Shimokata<sup>b</sup>, Hiroichi Nagai<sup>a</sup>

<sup>a</sup> Department of Pharmacology, Gifu Pharmaceutical University, Gifu, Japan

<sup>b</sup> Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

<sup>c</sup> Laboratory for Genetics of Allergic Disease, RIKEN SNP Research Center, Yokohama, Japan

<sup>d</sup> Pathophysiology Research Team, National Institute for Environmental Studies, Tsukuba, Japan

<sup>e</sup> Department of Molecular Immunology, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan

Received 5 December 2006; received in revised form 15 August 2007; accepted 5 September 2007

Available online 20 September 2007

### Abstract

*Dermatophagoides farinae* are known to be a common environmental allergen causing allergic asthma; however, little is known about their pathophysiological effect via the allergenicities in vivo. Therefore, we first established a mouse model of asthma induced by repeated instillations of *D. farinae*. Second, to investigate whether the asthmatic responses are Th2-dependent, we examined the effect of the deficiency of interleukin-4 (IL-4) receptor  $\alpha$  chain gene. Finally, we examined the effect of fluticasone propionate on this model. Mice were instilled with *D. farinae* without additional adjuvants into the trachea 8 times. After the final allergen instillation, the airway responsiveness to acetylcholine was measured, and bronchoalveolar lavage and histological examination were carried out. The instillation of the allergen-induced airway hyperresponsiveness, the accumulation of inflammatory cells and increases in the levels of Th2 cytokines and transforming growth factor- $\beta_1$  production in the bronchoalveolar lavage fluid dose dependently. The number of goblet cells in the epithelium and the extent of the fibrotic area beneath the basement membrane were also increased in the morphometric study. In contrast, the defect of IL-4/IL-13 signaling through IL-4 receptor  $\alpha$  chain completely abrogated all these responses. Furthermore, the simultaneous instillation of fluticasone propionate with the allergen showed significant inhibition or an inhibitory tendency of these changes. These findings demonstrate that the repetitive intratracheal instillations of *D. farinae* can induce airway remodeling through Th2-type inflammation, and that fluticasone propionate inhibits *D. farinae*-induced airway remodeling in mice, and this model would be useful for studying mechanisms involved in the development of allergic asthma.

© 2007 Elsevier B.V. All rights reserved.

**Keywords:** Airway; Asthma; Corticosteroid; *Dermatophagoides farinae*; Eosinophil; Goblet cell; IL-13; Mouse; Subepithelial fibrosis

### 1. Introduction

Bronchial asthma is one of the most common health problems in the worldwide, especially within industrialized societies, and

the prevalence rates have been increasing considerably over the last few decades (Mannino et al., 2002; Robertson et al., 2004; Verlato et al., 2003), for reason that are not yet completely understood. Changes in lifestyle and an increase in indoor allergen exposure caused by higher indoor temperature and humidity have been suggested as potential determinants, and it is reasonable to consider that environmental exposures to allergens are of primary importance for the prevalence and development of asthma, in genetically predisposed individuals, because genes

\* Corresponding author. Department of Pharmacology, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan. Tel.: +81 58 237 3931x286; fax: +81 58 237 8584.

E-mail address: [hirotnk@gifu-pu.ac.jp](mailto:hirotnk@gifu-pu.ac.jp) (H. Tanaka).

controlling the inflammatory responses, IgE production, cytokine and chemokine production, airway remodeling as well as airway function, has not changed significantly in the last few decades. Among allergens like ragweed, pollens, house dust mite, and cockroach, house dust mites including *Dermatophagoides farinae* and *Dermatophagoides pteronyssinus* are known to be principle allergen for the induction of asthma (Huss et al., 2001; Platts-Mills et al., 1997; Sporik et al., 1990), although the precise molecular mechanisms underlying the allergenicity of the allergens is not fully understood.

In contrast to the increased prevalence of allergic airway diseases, the control of bronchial asthma is becoming easier due to the wide use of inhaled corticosteroid. However, there are still some patients that are resistant to medical treatment. Airway remodeling, which is characterized by goblet cell hyperplasia/hypertrophy, subepithelial fibrosis and smooth muscle hyperplasia/hypertrophy (Aikawa et al., 1992; Heard and Hossain, 1973; Roche et al., 1989), is one of the causes of this problem. Although these structural changes have been considered to be characteristics of chronic and severe asthma, the latest clinical studies, using bronchial biopsy sampling, have demonstrated that they may exist even in patients with mild asthma and early in the disease process. Roche et al. reported that the deposition of collagen beneath the bronchial epithelium was also observed in young patients with mild atopic asthma (Roche et al., 1989), and Boulet et al. demonstrated that the degree of subepithelial collagen deposition in patients with mild asthma recently diagnosed was not significantly different from those of long-standing mild asthma (Boulet et al., 2000). Therefore, the comprehension of the mechanisms underlying airway remodeling is becoming an increasingly important problem, and the development of new anti-remodeling agents is strongly desired.

Animal models have been used for a long time to analyze the pathophysiology of human diseases and to seek new remedies for various diseases. In the case of bronchial asthma, guinea pigs, rats and mice have mainly been used (Pauluhn and Mohr, 2005). Although each animal has some good characteristics, recently, mice have been widely used because this species allows for the application in vivo of a broad range of immunological tools, including gene deletion technology (Kips et al., 2003). To date, in typical experiments using mice, they are systemically immunized to ovalbumin with a T helper type 2 (Th2)-skewing adjuvant, such as aluminum hydroxide gel, and challenged through airway application of the antigen in the form of an aerosol or an intranasal droplet aspiration. In fact, these murine models have been useful in understanding the immune responses, such as Th2 dominant phenotypes underlying allergic sensitization and airway eosinophilic inflammation (Wills-Karp, 2000), but it is still unknown how allergic sensitization via the mucosal surfaces of airways with aeroallergens, including house dust mite, is induced. Several studies have previously investigated aeroallergen-induced airway inflammation in vivo (Johnson et al., 2004; Sadakane et al., 2002; Yu et al., 1999). These studies demonstrated that repeated instillations of *D. farinae* without additional adjuvants can induce airway eosinophilic inflammation, probably through Th2-polarized responses in mice;

however, it remains to be determined whether the repeated inoculation of *D. farinae* can induce local Th2 responses and airway remodeling, as well as airway inflammation and airway hyperresponsiveness, and whether the allergic responses induced by this allergen are Th2-dependent. Moreover, the effect of fluticasone propionate on *D. farinae*-induced airway eosinophilic inflammation, hyperresponsiveness to acetylcholine and remodeling in vivo has not been elucidated.

Therefore, to address these unanswered questions, we first established a *D. farinae*-induced airway inflammation using mice, which was locally immunized without any additional adjuvants. Then, we examined the characteristics of this model regarding the local Th1/Th2 balance, the development of airway remodeling and the peculiarity of the allergen by comparing with the characteristics of the ovalbumin-instilled mice. Furthermore, to clarify whether these allergic responses are Th2-dependent, we used interleukin (IL)-4 receptor  $\alpha$  chain gene-deficient mice because the IL-4 receptor  $\alpha$  chain is a common receptor for IL-4 and IL-13, which are both critical for Th2 polarization and the development. Finally, we examined the effect of fluticasone propionate, one of the strongest anti-inflammatory medicines available at the moment, on this model, especially on airway remodeling.

## 2. Materials and methods

### 2.1. Animals

Seven-week-old male BALB/c mice were purchased from Japan SLC (Shizuoka, Japan). IL-4 receptor  $\alpha$  chain gene-deficient mice (IL-4R $\alpha$ ; BALB/c background) (Noben-Trauth et al., 1999; Noben-Trauth et al., 1997) were purchased from Immuno-Biological Laboratories, Co. Ltd. (Takasaki, Japan). The animals were housed in plastic cages in an air-conditioned room at  $22 \pm 1$  °C with a relative humidity of  $60 \pm 5\%$ , fed a standard laboratory diet and given water *ad libitum*. Experiments were undertaken following the guidelines for the care and use of experimental animals of the Japanese Association for Laboratory Animals Science in 1987.

### 2.2. Agents

The following drugs and chemicals were purchased commercially and used: crude extract of *D. farinae* (LSL Co., Tokyo, Japan), ovalbumin (chicken egg white, grade V, Sigma, St. Louis, MO., USA), dimethyl sulfoxide (DMSO, Nacalai Tesque, Inc., Kyoto, Japan), phosphate-buffered saline (PBS, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan), halothane (Takeda Chemical Industries, Ltd, Osaka, Japan), acetylcholine chloride (Nacalai Tesque, Inc.), bovine serum albumin (Seikagaku Kogyo, Tokyo, Japan), Türk solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan), pancuronium bromide (Sigma), sodium pentobarbitone (Abbott Lab., Chicago, IL, USA), disodium ethylenediaminetetraacetic acid (EDTA-2Na; Nacalai Tesque) and Diff-Quick solution (International Reagent Corp., Ltd., Kobe, Japan). Fluticasone propionate was kindly given to us by GlaxoSmithKline, Japan.



### 2.3. Experimental protocol

Mice were instilled 8 times with *D. farinae* (4 µg or 20 µg of protein in 100 µl of PBS) or PBS alone into the trachea using a polyethylene cannula under halothane anesthesia (Fig. 1A). In the ovalbumin-induced airway inflammation model, mice were instilled with ovalbumin in the same way. Forty-eight hours after the final antigen challenge, the airway responsiveness to acetylcholine was measured, and bronchoalveolar lavage and histological study were performed.

### 2.4. Treatment with fluticasone propionate

Fluticasone propionate was dissolved in DMSO and diluted in PBS to a final concentration of 0.01%. Fluticasone propionate was instilled with *D. farinae* on day 14, 15, 21, 22, 28 and 29, and without the allergen on days 13, 20 and 27 according to previously described methods (Fig. 1B). The *D. farinae*-instilled group mice, which were the control group mice, were administrated 20 µg of the allergen with 0.01% DMSO.

### 2.5. Bronchoalveolar lavage

To evaluate airway inflammation, we examined the accumulation of inflammatory cells in bronchoalveolar lavage fluid. Experiments were performed according to previously described methods (Tanaka et al., 2001). Animals were killed with an intraperitoneal injection of sodium pentobarbitone (100 mg/kg). The trachea was cannulated and the left bronchi were tied for histological examination. Then, the right air lumen was washed 4 times with 0.5-ml calcium- and magnesium-free PBS containing 0.1% bovine serum albumin and 0.05 mM EDTA-2Na. This procedure was repeated three times (total volume; 1.3 ml, recovery >85%). The bronchoalveolar lavage fluid from each animal was pooled in a plastic tube, cooled on ice and centrifuged (150 ×g) at 4 °C for 10 min. Cell pellets were resuspended in the same buffer (0.5 ml). Bronchoalveolar lavage fluid was stained with Türk solution and the number of nucleated cells was counted in a Burker chamber. A differential count was made on a smear prepared with a cytocentrifuge

(Cytospin II, Shandon, Cheshire, England) and stained with Diff-Quick solution (based on standard morphological criteria) of at least 300 cells (magnification ×500). The supernatant of the bronchoalveolar lavage fluid was stored at –80 °C for the determination of cytokine production.

### 2.6. Cytokine levels in the bronchoalveolar lavage fluid

The amount of cytokine in the supernatant of the bronchoalveolar lavage fluid was measured using the enzyme-linked immunosorbent assay (ELISA) (Endogen Inc., Woburn, MA, USA for IL-4, IL-5 and interferon (IFN)-γ; R&D Systems Inc., Minneapolis, MN, USA for IL-13). The transforming growth factor (TGF)-β<sub>1</sub> content in the bronchoalveolar lavage fluid was also measured using ELISA (Genzyme Tecne, Minneapolis, MN, USA), which can detect mouse TGF-β<sub>1</sub> protein, because of the high homology of TGF-β<sub>1</sub> across species. The assay detects only the active form of TGF-β<sub>1</sub>. Each sample was activated before measuring, according to the manufacturer's recommendations. The detection limit of each kit was 5 pg/ml for IL-4 and IL-5, 10 pg/ml for IFN-γ, 1.5 pg/ml for IL-13, or 7 pg/ml for TGF-β<sub>1</sub>, respectively.

### 2.7. Measurement of airway function

Measurement of the bronchial responsiveness to intravenous acetylcholine was performed as previously described (Komai et al., 2003; Tanaka et al., 2001). Briefly, to measure the airway responsiveness to acetylcholine, mice were anaesthetized with sodium pentobarbital (60 mg/kg, i.p.) and the jugular vein was cannulated for the intravenous injection of acetylcholine. Mice were injected with pancuronium bromide (0.1 mg/kg, i.v.) to stop spontaneous respiration, and animals were ventilated with a rodent ventilator (New England Medical Instruments Inc., Medway, MA, USA). Bronchoconstriction was measured according to the overflow method, using a bronchospasm transducer (Ugo Basil 7020, Milan, Italy) connected to the tracheal cannula. To measure airway responsiveness to acetylcholine, changes in the respiratory overflow volume were measured using increasing doses of acetylcholine. The increase in respiratory overflow volume induced by acetylcholine was represented as a percentage of the maximal overflow volume (100%) obtained by clamping the tracheal cannula. The area under the curve (AUC) calculated from dose–response curves for acetylcholine is expressed as the magnitude of airway hyperresponsiveness. Briefly, each dose was converted logarithmically, and then AUC was calculated and represented as arbitrary units (Tanaka et al., 2001).

### 2.8. Histological study

The left lungs were distended by the injection of 10% buffered formalin via the trachea, excised and immersed in the same fixative with the trachea clamped for 24 h. Tissues were sliced and embedded in paraffin, and 6 µm sections were stained with periodic acid-Schiff (PAS) and Masson-trichrome for light microscopy examination.




Fig. 1. Experimental protocol for *Dermatophagoides farinae* (Der f)-induced airway inflammation in BALB/c mice. A: *D. farinae* was instilled 8 times into the airways of BALB/c mice. B: Fluticasone propionate (FP) was administrated via the trachea with or without *D. farinae*, starting from the day before the third instillation of the allergen. i.t., intratracheal injection.

Examination of goblet cell hyperplasia was carried out with the PAS-stained histological preparations of the left lobe using a Leica image analysis system (Leica, Cambridge, UK). Using a  $\times 10$  objective, 4 typical areas were chosen from the largest visible airway, which, in these horizontal sections through the hilus, was the left main bronchus. Changing to a  $\times 40$  objective, in each chosen area, which corresponded to one microscopic field, the hyperplasia of the goblet cells in the epithelial lining was expressed by a score according to the percentage of the goblet cells in the epithelial cells described below. The length of the epithelial basement membrane of the bronchus of one area was 500  $\mu\text{m}$  and over. To minimize the sampling errors, the 5-point scoring system (grade 0–4) (Tanaka et al., 2001) was adopted: grade 0, no goblet cells; grade 1, <25%; grade 2, 25–50%; grade 3, 50–75%; grade 4,  $\geq 75\%$ . The mean score of the total epithelial cells in the 4 areas of one mouse were counted. The mean scores of hyperplasia of the goblet cells were calculated in 5–9 animals.

Masson-trichrome stained sections were used for the assessment of the thickness of the epithelial layer and the detection of subepithelial fibrosis using a Leica image analysis system (Leica). As described above, using a  $\times 10$  objective, 3 representative areas were chosen, avoiding the selection of the furcation of the bronchus and the surrounding blood vessels in the largest airway. Changing a  $\times 40$  objective, epithelial basement membrane areas 250  $\mu\text{m}$  and over were selected, and the thickness of the epithelial layer and the fibrotic area (stained in blue) 30  $\mu\text{m}$  beneath the basement membrane of the standardized sampling points were measured. The mean of the thickness of the epithelial layer and the fibrotic area divided by the basement membrane length were calculated in 5–9 animals.

### 2.9. Statistical analysis

Values are presented as the mean with standard error. Statistical significance between two groups was estimated using the two-tailed Student's *t*-test or the Mann–Whitney's *U*-test after the variances of the data were evaluated with the *F*-test. To define significant differences among PBS-instilled animals and *D. farinae*-instilled animals, and among the control animals and fluticasone propionate-treated animals, the data were subjected to Bartlett's analysis, followed by a parametric or a non-parametric Dunnett's multiple range test. A *P* value less than 0.05 was considered to be significant.

## 3. Results

### 3.1. The effect of repeated instillations of *D. farinae* into the mouse trachea on airway responsiveness to acetylcholine, Th1/Th2 immune responses and inflammatory infiltrates in the airways

To examine the effect of repeated instillation of *D. farinae* into the mouse trachea on Th1/Th2 immune responses, airway




Fig. 2. Effect of repeated allergen instillation on airway responsiveness to acetylcholine and inflammatory infiltrates in the bronchoalveolar lavage fluid in BALB/c mice. A: Airway responsiveness to acetylcholine 48 h after the final allergen challenge. B: Area under the curve (AUC) calculated from the dose–response curves of bronchoconstriction for acetylcholine (range: 31.25–2000  $\mu\text{g}/\text{kg}$ ). C: Number of leukocytes in the bronchoalveolar lavage fluid 48 h after the final allergen challenge. Values represent the mean  $\pm$  S.E.M. of seven to eight mice in each group. PBS, phosphate-buffered saline-instilled; Der f, *Dermatophagoides farinae*-instilled; N.D., not detected; \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001 (vs PBS).

inflammation and airway responsiveness to acetylcholine, we examined the airway responsiveness to acetylcholine, inflammatory infiltrates and cytokine production in the bronchoalveolar lavage fluid, and the histopathological changes in the airways. Repeated allergen instillations induced increases in the airway responsiveness to acetylcholine (Fig. 2A and B) and the numbers of inflammatory cells, including eosinophils, lymphocytes and neutrophils in the bronchoalveolar lavage fluid in a dose-dependent manner (Fig. 2C). Furthermore, as shown in Table 1, the levels of Th2 cytokines, IL-5 and IL-13, in the bronchoalveolar lavage fluid were also significantly increased; whereas, the level of Th1 cytokine, IFN- $\gamma$ , in the bronchoalveolar lavage fluid was decreased by the allergen instillations in a dose-dependent fashion. However, there were no

Table 1

Cytokine production in bronchoalveolar lavage fluid and structural changes in the airways 48 h after the final allergen challenge in BALB/c mice

Treatment	IL-4 (pg/ml)	IL-5 (pg/ml)	IL-13 (pg/ml)	IFN $\gamma$ (pg/ml)	Goblet cell hyperplasia (arbitrary unit)	Goblet cell hypertrophy ( $\mu\text{m}$ )	Fibrotic area (Area/BM)	TGF- $\beta_1$ (pg/ml)
PBS	20.7 $\pm$ 6.1	N.D.	0.8 $\pm$ 0.4	164.5 $\pm$ 10.3	0.08 $\pm$ 0.05	32.3 $\pm$ 1.7	5.5 $\pm$ 0.7	30.6 $\pm$ 6.2
Der f 4 $\mu\text{g}$	20.4 $\pm$ 8.4	0.9 $\pm$ 0.7	1.6 $\pm$ 0.4	149.8 $\pm$ 10.7	2.82 $\pm$ 0.22	53.5 $\pm$ 5.5 b	10.4 $\pm$ 1.0 b	42.8 $\pm$ 15.5
Der f 20 $\mu\text{g}$	25.0 $\pm$ 5.1	7.1 $\pm$ 2.5	10.6 $\pm$ 2.5 c	131.9 $\pm$ 2.5 a	3.83 $\pm$ 0.17 c	77.3 $\pm$ 7.9 c	15.6 $\pm$ 0.9 c	217.3 $\pm$ 38.9 b

Values represent the means $\pm$ S.E.M. of 7–8 animals in each group. BM, Basement membrane; Der f, *Dermatophagoides farinae*; N.D., not detected. a  $P$ <0.05; b  $P$ <0.01; c  $P$ <0.001 (vs PBS).

significant differences in the levels of IL-4 in the bronchoalveolar lavage fluid between the PBS group and the allergen group (Table 1).




Fig. 3. Effect of IL-4 receptor  $\alpha$  chain gene deficiency on the allergen-induced airway hyperresponsiveness to acetylcholine, increases in the numbers of total leukocytes and eosinophils and the production of IL-13 in the bronchoalveolar lavage fluid, and decreases in IFN- $\gamma$  production in the bronchoalveolar lavage fluid in BALB/c mice. Forty-eight hours after the final allergen instillation, the airway responsiveness to acetylcholine was measured, and bronchoalveolar lavage and histological examination were carried out. Values represent the mean $\pm$ S.E.M. of seven to nine mice in each group. PBS, phosphate-buffered saline-instilled; Der f, *Dermatophagoides farinae*-instilled; N.D., not detected; \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 (vs PBS, Student's  $t$ -test or Mann–Whitney's  $U$ -test); † $P$ <0.05, †† $P$ <0.01, ††† $P$ <0.001 (vs WT, Dunnett's test).

Next, to clarify whether allergic responses induced by *D. farinae* are Th2-dependent or not, we examined the effect of IL-4 receptor  $\alpha$  chain gene deficiency using the gene-knockout mice compared with wild-type (BALB/c) mice. As shown in Fig. 3, the defect of IL-4/IL-13 signaling through IL-4 receptor  $\alpha$  chain clearly abrogated the airway hyperresponsiveness ( $P$ <0.001, Fig. 3A and B), airway eosinophilia ( $P$ <0.001, Fig. 3C), and imbalance in the IL-13/IFN- $\gamma$  production in the bronchoalveolar lavage fluid ( $P$ <0.001 for IL-13 or  $P$ <0.05 for IFN- $\gamma$ , Fig. 3D) induced by the allergen administration.

Then, to investigate the peculiarity of *D. farinae* in this model, mice were instilled with the same amount of ovalbumin as protein content instead of the allergen in a similar manner. Neither airway hyperresponsiveness, the accumulation of inflammatory cells into the airways or increases in the Th2 cytokine level in the bronchoalveolar lavage fluid was observed in the ovalbumin-instilled group (data not shown).




Fig. 4. Histological analysis of lung section with periodic acid-Schiff (A–C) and with Masson-trichrome (D–F) 48 h after the final allergen challenge in BALB/c mice. (A and D) PBS-instilled animal; (B and E) 4  $\mu\text{g}$  of *D. farinae*-instilled animal; (C and F) 20  $\mu\text{g}$  of *D. farinae*-instilled animal. Scale bar 200  $\mu\text{m}$ .

Table 2

Effect of IL-4 receptor  $\alpha$  chain gene deficiency on *Dermatophagoides farinae* (Der f)-induced airway remodeling in BALB/c mice

Genotype	Treatment	Goblet cell hyperplasia (arbitrary units)	Goblet cell hypertrophy ( $\mu\text{m}$ )	Fibrotic area (Area/BM)	TGF- $\beta_1$ (pg/ml)
Wild-type	PBS	0.43 $\pm$ 0.12	0.43 $\pm$ 0.12	5.41 $\pm$ 0.44	55.5 $\pm$ 12.4
	Der f 20 $\mu\text{g}$	3.92 $\pm$ 0.04 b	3.92 $\pm$ 0.04 b	18.62 $\pm$ 2.10 b	334.8 $\pm$ 23.9 b
IL-4 $\alpha$ chain gene deficiency	PBS	0.44 $\pm$ 0.09	0.44 $\pm$ 0.09	5.62 $\pm$ 0.52	46.4 $\pm$ 3.0
	Der f 20 $\mu\text{g}$	0.57 $\pm$ 0.12 c	0.57 $\pm$ 0.12 c	5.73 $\pm$ 0.36 c	81.8 $\pm$ 7.8 a, c

Values represent the means $\pm$ S.E.M. of 7–9 animals in each group. BM, Basement membrane; TGF, transforming growth factor.a  $P$ <0.01; b  $P$ <0.001 (vs PBS group); c  $P$ <0.001 (vs Wild-type).

### 3.2. The effect of repeated instillations of *D. farinae* into the mouse trachea on airway remodeling

Fig. 4 shows the representative sections of each group stained with PAS for the detection of goblet cells and with Masson-trichrome for the detection of the fibrotic area. Repeated instillations of *D. farinae* caused goblet cell hyperplasia/hypertrophy in the epithelium and enlarged the area of subepithelial fibrosis dose dependently. These structural changes were mainly observed in the central large airways although the peripheral airways were mostly in tact.

To examine these histological changes quantitatively, goblet cell hyperplasia/hypertrophy and subepithelial fibrosis were evaluated by a score of PAS positive cells (stained in purple), the thickness of the epithelial layer and the area of fibrosis (stained in blue). As shown in Table 1, each score was significantly increased by repeated allergen inoculations in a dose-dependent manner. Furthermore, the level of profibrotic cytokine, TGF- $\beta_1$ , in the bronchoalveolar lavage fluid was also dramatically increased by the instillation of *D. farinae* (Table 1). In contrast, these histopathological changes in the airways and increased TGF- $\beta_1$  production in the bronchoalveolar lavage fluid were completely diminished in IL-4 receptor  $\alpha$  chain gene-deficient mice ( $P$ <0.001, Table 2).

### 3.3. The effect of fluticasone propionate on *D. farinae*-induced airway hyperresponsiveness, eosinophilic inflammation and Th1/Th2 immune responses

To investigate the effect of fluticasone propionate on the *D. farinae*-induced asthma-like phenotypes, mice were given 100–1000  $\mu\text{g}/\text{kg}$  fluticasone propionate via an intratracheal route with the allergen on days 14, 15, 21, 22, 28 and 29, and without the allergen on days 13, 20 and 27 (Fig. 1B). To determine the initial timing of fluticasone propionate treatment, we examined the time course study for repeated allergen instillation in this protocol, and observed increases in the number of eosinophils and the level of IL-13 in the bronchoalveolar lavage fluid on day 17, 48 h after the fourth allergen instillation (data not shown), suggesting that sensitization with *D. farinae* was established and allergic responses in the airways were ongoing at that time.

Fig. 5 shows the effect of fluticasone propionate on allergen-induced airway hyperresponsiveness and leukocyte infiltrates in the bronchoalveolar lavage fluid. Repeated instillations of *D. farinae* significantly increased the airway responsiveness to acetylcholine and the number of inflammatory cells in the

bronchoalveolar lavage fluid. Treatment with fluticasone propionate, at doses of 300 and 1000  $\mu\text{g}/\text{kg}$ , significantly inhibited the increases in the numbers of neutrophils,




Fig. 5. The effect of fluticasone propionate (FP) on the allergen-induced airway hyperresponsiveness to acetylcholine and on the number of leukocytes in the bronchoalveolar lavage fluid. Forty-eight hours after the final allergen instillation, the airway responsiveness to acetylcholine was measured, and bronchoalveolar lavage was carried out. A: Airway responsiveness to acetylcholine 48 h after the final allergen challenge. B: Area under the curve (AUC) calculated from the dose-response curves of bronchoconstriction for acetylcholine (range: 31.25–2000  $\mu\text{g}/\text{kg}$ ). C: Number of leukocytes in the bronchoalveolar lavage fluid 48 h after the final allergen challenge. Values represent the mean $\pm$ S.E.M. of five to seven mice in each group. Der f, *Dermatophagoides farinae*; PBS, phosphate-buffered saline-instilled; Der f, 20  $\mu\text{g}$  of *D. farinae*-instilled; FP, Der f and fluticasone propionate-instilled; N.D., not detected; \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 (vs Der f, Student's  $t$ -test or Mann-Whitney's  $U$ -test); † $P$ <0.05, †† $P$ <0.01, ††† $P$ <0.001 (vs WT, Dunnett's test).

Table 3

Effect of fluticasone propionate (FP) on *Dermatophagoides farinae* (Der f)-induced Th2-polarized cytokine production and airway remodeling in BALB/c mice

Treatment	IL-4 (pg/ml)	IL-5 (pg/ml)	IL-13 (pg/ml)	IFN $\gamma$ (pg/ml)	Goblet cell hyperplasia (arbitrary unit)	Goblet cell hypertrophy ( $\mu$ m)	Fibrotic area (Area/BM)	TGF- $\beta_1$ (pg/ml)
PBS	6.1 $\pm$ 3.2	1.2 $\pm$ 0.7a	0.4 $\pm$ 0.4 b	168.6 $\pm$ 7.1	0.17 $\pm$ 0.05 b	36.3 $\pm$ 1.6 a	5.1 $\pm$ 0.6 b	21.6 $\pm$ 3.9 b
Der f	7.2 $\pm$ 4.6	13.1 $\pm$ 3.6	6.6 $\pm$ 1.3	149.8 $\pm$ 15.2	3.54 $\pm$ 0.07	58.4 $\pm$ 5.8	12.6 $\pm$ 0.5	253.7 $\pm$ 46.3
FP 100 $\mu$ g/kg	1.2 $\pm$ 1.2	10.9 $\pm$ 2.3	3.4 $\pm$ 1.7	139.5 $\pm$ 9.2	3.36 $\pm$ 0.20	52.5 $\pm$ 1.3	8.7 $\pm$ 0.6 e	133.8 $\pm$ 35.9
FP 300 $\mu$ g/kg	8.8 $\pm$ 4.4	5.2 $\pm$ 2.1	2.3 $\pm$ 0.8	171.8 $\pm$ 10.1	2.82 $\pm$ 0.22	47.9 $\pm$ 3.3	7.9 $\pm$ 0.3 e	56.7 $\pm$ 9.3 d
FP 1000 $\mu$ g/kg	5.3 $\pm$ 3.4	2.5 $\pm$ 0.9 d	0.7 $\pm$ 0.3 d	173.1 $\pm$ 13.7	1.35 $\pm$ 0.37 d	41.7 $\pm$ 2.7 c	5.3 $\pm$ 0.5 e	45.8 $\pm$ 8.8 e

Values represent the means $\pm$ S.E.M. of 5–7 animals in each group. BM, Basement membrane; TGF, transforming growth factor.a  $P$ <0.05; b  $P$ <0.01 (vs Der f group, Mann–Whitney's  $U$ -test); c  $P$ <0.05; d  $P$ <0.01; e  $P$ <0.001 (vs Der f group, Dunnett's test).

eosinophils and lymphocytes in the bronchoalveolar lavage fluid; whereas, the drug showed a tendency to inhibit airway hyperresponsiveness (Fig. 5). Furthermore, in parallel with the effect on airway eosinophilic inflammation, the increased levels of Th2 cytokines, IL-5 and IL-13, in the bronchoalveolar lavage fluid was almost reversed by fluticasone propionate treatment in a dose-dependent fashion (Table 3).

#### 3.4. The effect of fluticasone propionate on the development of airway structural changes induced by *D. farinae*

Fig. 6 shows the representative lung specimens of the *D. farinae*-instilled group and the fluticasone propionate-treated group. The quantitative findings of histopathological examination and TGF- $\beta_1$  production in each group are shown in Table 3.

As shown in Fig. 6 and Table 3, severe goblet cell hyperplasia/hypertrophy, marked subepithelial fibrosis and the increased production of TGF- $\beta_1$  in the bronchoalveolar lavage fluid were all observed in the allergen-instilled group compared with those in the PBS-instilled group. In contrast, the treatment with fluticasone propionate, at a dose of 1000  $\mu$ g/kg, during allergen challenge significantly inhibited these quantitative changes.




Fig. 6. Histological analysis of a lung section with periodic acid-Schiff (A and B) and with Masson-trichrome (C and D) 48 h after the final allergen challenge in fluticasone propionate-treated mice. (A and C) 20  $\mu$ g of *Dermatophagoides farinae*-instilled animals; (B and D) fluticasone propionate-treated animals. Scale bar 200  $\mu$ m.

#### 4. Discussion

Bronchial asthma is a chronic inflammatory airway disease that is characterized by eosinophil inflammation, bronchial hyperresponsiveness and airway remodeling in pathophysiological studies (Cohn et al., 2004). In addition, many clinical and experimental studies suggest that Th2 cells that secrete IL-4, IL-5 and IL-13 have important functions in directing and maintaining the airway inflammatory processes (Robinson et al., 1992; Temann et al., 1997; Tomkinson et al., 2001). To understand the basic cellular and molecular mechanisms of allergic sensitization and airway inflammation, various animal models that possess these characteristics have provided valuable information on several aspects of asthma, and we reported the ovalbumin-induced allergic asthma model in mice by systemic sensitization and repeated allergen exposure (Nagai et al., 1997; Tanaka et al., 2001). Although this model is useful for the analysis of specific IgE-dependent airway eosinophilic inflammation, it is difficult to investigate the onset of the disease (especially local sensitization and challenge) and the specificity of relevant allergens that trigger human asthma. Therefore, we established a mouse model of allergic asthma by the intratracheal instillation of *D. farinae* without additional adjuvants.

In the present study, we showed *D. farinae*-induced airway eosinophilic inflammation in mice by the local instillation. Our mouse model is characterized by eosinophil infiltrates into the airways, increases in the levels of IL-5 and IL-13 in the bronchoalveolar lavage fluid, a decrease in the level of IFN- $\gamma$  in the bronchoalveolar lavage fluid, and airway hyperresponsiveness to acetylcholine in a dose-dependent manner. Furthermore, these asthma-like phenotypes were completely abrogated in IL-4 receptor  $\alpha$  chain gene-deficient mice, suggesting that IL-4 and/or IL-13 play a predominant role in the induction and development of *D. farinae*-induced Th2 responses. In addition, another foreign protein, ovalbumin, could not induce asthmatic responses at all in the same protocol. Indeed, it has been reported that the repeated inoculation of *D. farinae* into the trachea (Yu et al., 1999) or the nose (Johnson et al., 2004) of mice induces airway eosinophilia, but these reports are limited to the increases in Th1/Th2 cytokines in the bronchoalveolar lavage fluid or in Th2 cytokines in the allergen-stimulated splenocytes, respectively. Thus, this is the first report to prove directly that *D. farinae* by itself has the capacity to induce the imbalance of Th2/Th1 responses in the airways and to promote local Th2 type immune responses through IL-4 receptor  $\alpha$  chain.

House dust mite is known to be composed of mixed materials, including *D. farinae* and pteronyssinus. Moreover, *D. farinae* contains at least 2 major allergens (*D. farinae* 1 and 2) (King et al., 1994). As described above, it was reported that repeated ovalbumin inhalation to sensitized mice induced tolerance (Holt et al., 1981; Sakai et al., 2001; Swirski et al., 2002); however, in the case of *D. farinae*, the number of eosinophils gradually increased, even after 24 instillations (unpublished data), suggesting that *D. farinae* does not easily induce tolerogenic responses. Thus, there seems to be some different characteristics in the allergen compared to ovalbumin, including their proteolytic activities. More importantly, the molecular mechanisms underlying in mucosal sensitization, airway inflammation and airway remodeling by repeated allergen instillation might be different even though each phenotype like Th2-polarized immune responses is quite similar. Therefore, further experiments are needed to clarify which types of allergen and/or what kinds of components are responsible for these asthmatic phenotypes in this model.

The present data demonstrated that no increase of the IL-4 level was observed 48 h after the final allergen challenge; whereas, there were significant increases in the levels of Th2 cytokines and a decrease in Th1 cytokine production in the bronchoalveolar lavage fluid, respectively. It may be due to the difference of kinetics in the cytokine production after allergen challenge. For instance, Ohkawara et al. demonstrated that the peak level of IL-4 and IL-5 in the fluid occurred 24 h after antigen challenge in the ovalbumin-sensitized mice (Ohkawara et al., 1997). While a remarkable increase in the IL-5 level in the fluid was observed from 3 h after the challenge and continued for 5 days, the kinetics of the IL-4 level in the fluid were much shorter than those of IL-5. In our study, we measured the cytokine levels 48 h after the last antigen challenge; therefore, the peak level of IL-4 in the BALF might have passed.

In contrast to the level of IL-4 in the airways, we detected increased levels of *D. farinae*-specific IgG1 on day 13, and the levels were much increased on day 27 and 31 using an allergen-coated ELISA system (data not shown). Serum allergen-specific IgE was also detected on day 27 by passive cutaneous anaphylaxis in rats (data not shown). Therefore, we provide evidence of Th2-polarized systemic immune responses in the allergen-instilled mice.

Mucus hypersecretion from hyperplastic goblet cells causes airway mucous plugging, especially in the peripheral airways of asthmatics. Mucous plugging has been reported to be an important factor in the mortality rates associated with severe acute asthma (Aikawa et al., 1992; Saetta et al., 1991). Recently, several observations have implicated Th2 cytokines, IL-4, IL-9 and IL-13, in goblet cell metaplasia of mice (Grunig et al., 1998; Louahed et al., 2000; Temann et al., 1997; Wills-Karp et al., 1998). In addition, IL-4 and IL-13 have been shown to be major contributing factors for allergen (ovalbumin)-induced mucus production via IL-4 receptor  $\alpha$  chain in an allergic mouse model (Cohn et al., 1999; Kuperman et al., 2005). However, it is not clear whether *D. farinae*-induced mucous production is dependent on IL-4 receptor  $\alpha$  chain in vivo. Therefore, we investigated the dependency using IL-4 receptor  $\alpha$  chain gene-

deficient mice. As a result, goblet cell hyperplasia/hypertrophy caused by the repeated allergen challenge was completely dependent on IL-4 receptor  $\alpha$  chain. It is difficult to determine whether the allergen-induced mucous metaplasia is due to a Th2-polarized immune response in the airways, or to the direct effects of *D. farinae*. In the present study, marked increases in goblet cells and goblet cell hypertrophy in the epithelium were observed in both the low dose (4  $\mu$ g) and high dose (20  $\mu$ g) *D. farinae*-instilled groups, and their extents were comparable; whereas, Th2 cytokine production and the imbalance of the Th1/Th2 responses in the airways were more prominent in the high dose group. Therefore, it is possible that *D. farinae* directly affected the ciliated epithelial cells to transform/differentiate into goblet cells, probably through their protease activity, and that their protease activity influenced the allergenicity, which can induce Th2-polarized immune responses dependent on IL-4 receptor  $\alpha$  chain, although further experiments are needed to clarify whether these protease activities are involved in their transformation/differentiation.

In histological analysis, the fibrotic areas under the basal lamina of the central airways were quantitatively evaluated, and increases in the areas were observed in a dose-dependent fashion. Furthermore, an increase in the TGF- $\beta_1$  level in the bronchoalveolar lavage fluid was observed in a dose-dependent fashion, and the increased production after the repeated instillation of *D. farinae* was IL-4/IL-13 dependent through IL-4 receptor  $\alpha$  chain. TGF- $\beta_1$  plays a central role in the pathogenesis of a variety of fibrotic disorders. It stimulates the production of extracellular matrix proteins and inhibits the formation of extracellular proteases. An increase in the TGF- $\beta_1$  levels was observed in the clinical specimens of fibrotic kidney disease, hepatic fibrosis and pulmonary fibrosis (Blobe et al., 2000). In asthmatic patients, the bronchoalveolar lavage study or biopsy specimens indicated an increase in the TGF- $\beta_1$  levels, and its expression levels correlated with the severity of the disease and the degree of subepithelial fibrosis (Redington et al., 1997; Vignola et al., 1997). We previously reported that the increased levels of TGF- $\beta_1$  in the bronchoalveolar lavage fluid were significantly correlated with fibrotic changes in the morphometric studies following ovalbumin sensitization and challenge in mice (Komai et al., 2003; Tanaka et al., 2001), and that eosinophils and myofibroblasts play a critical role in the development of subepithelial fibrosis in mice (Tanaka et al., 2004). Therefore, it is also possible that these cells that infiltrated around the airways can produce the fibrogenic factor in this model.

Now, inhaled corticosteroid maintains its position as a first-line therapy for bronchial asthma. Several clinical studies have suggested that inhaled corticosteroid is effective for airway inflammation and structural changes, such as the thickness of the subepithelial basement membrane (Olivieri et al., 1997; Sont et al., 1999). However, there are conflicting findings about the effect on airway remodeling (Jeffery et al., 1992; Lundgren et al., 1988). Therefore, we investigated the effect of the corticosteroid, fluticasone propionate, on this model. As a result, it was found that fluticasone propionate dramatically inhibited airway eosinophilic inflammation and increased Th2

cytokines and TGF- $\beta_1$  productions in the bronchoalveolar lavage fluid, and that fluticasone propionate showed a tendency to inhibit the airway hyperresponsiveness to acetylcholine. Furthermore, goblet cell hyperplasia in the airways and the fibrotic area beneath the basal lamina of the central airways were significantly improved by fluticasone propionate treatment in a dose-dependent manner. These findings suggest that inhaled corticosteroid can inhibit *D. farinae*-induced airway remodeling, probably through inhibiting Th2-mediated airway eosinophilic inflammation. However, there is a discrepancy in the fluticasone propionate doses between the effects on inflammatory infiltrates and airway remodeling/airway hyperresponsiveness in the present study. Vanacker et al. also demonstrated that fluticasone propionate prevented antigen-induced airway inflammation and structural changes using a rat asthma model, and they also argued that a higher dose of inhaled corticosteroid is needed to prevent allergen-induced structural changes than that required to inhibit eosinophil recruitment (Vanacker et al., 2002). Furthermore, Boulet et al. recently demonstrated that there is no significant difference in airway inflammation and subepithelial collagen deposition in steroid-naïve patients with mild recently diagnosed vs long-standing asthma, and that there was no significant improvement in the airway hyperresponsiveness after high doses of inhaled corticosteroids between these two groups (Boulet et al., 2000). These findings suggest that there are irreversible airway structural and/or physiological changes, despite appropriate and aggressive anti-inflammatory therapies, which may explain the reason why airway remodeling and airway hyperresponsiveness could not be normalized in some patients.

Another question to be addressed is whether fluticasone propionate is effective for airway hyperresponsiveness in this model. We observed that fluticasone propionate showed a tendency to inhibit allergen-induced airway hyperresponsiveness, but it was not significant. Many clinical studies and a few animal studies suggested that inhaled corticosteroid improved airway hyperresponsiveness (Olivieri et al., 1997; Sont et al., 1999); however, these improvements mainly resulted from the strong anti-inflammatory effects of the steroids. The relevance between airway hyperresponsiveness and airway remodeling is always a matter of concern, and undoubtedly, clinical biopsy specimens cannot assess the airways as a whole. Moreover, airway hyperresponsiveness did not return to within normal limits in most long-term studies, although it was improved (van Essen-Zandvliet et al., 1992). Therefore, our result may be due to the remaining airway structural changes, especially goblet cell hyperplasia or other factors; however, little is known about the effect of steroids on airway remodeling, especially in vivo, and further experiments will be needed.

In conclusion, we established a mouse model of atopic asthma, which was locally immunized with a major indoor allergen, *D. farinae*, without additional adjuvants. This model clearly demonstrated the local Th2-dominant inflammation and airway remodeling feature, and those parameters were improved by inhaled corticosteroid. We believe that this model is a useful tool for the investigation of mechanisms and the development of new remedies for airway remodeling in atopic asthma.

## Acknowledgements

This work was supported in part by the Ministry of Health, Labor and Welfare (Japan), Health and Labour Science Research Grants, Research on Allergic Disease and Immunology, the Ministry of Education, Culture, Sports, Science and Technology (Japan) (to H.N.), Grants-in-Aid for Scientific Research C 16616005 (to H.T.), and the Takeda Science Foundation (to H.T.). This study was also supported in part by a donation from the late Professor Emeritus, Akihide Koda, for which we are very grateful. The authors thank Mr. Daniel Mrozek for his skillful assistance in the preparation of this manuscript.

## References

- Aikawa, T., Shimura, S., Sasaki, H., Ebina, M., Takishima, T., 1992. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. *Chest* 101, 916–921.
- Blobe, G.C., Schiemann, W.P., Lodish, H.F., 2000. Role of transforming growth factor beta in human disease. *N. Engl. J. Med.* 342, 1350–1358.
- Boulet, L.P., Turcotte, H., Laviolette, M., Naud, F., Bernier, M.C., Martel, S., Chakir, J., 2000. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. *Am. J. Respir. Crit. Care Med.* 162, 1308–1313.
- Cohn, L., Elias, J.A., Chupp, G.L., 2004. Asthma: mechanisms of disease persistence and progression. *Annu. Rev. Immunol.* 22, 789–815.
- Cohn, L., Homer, R.J., MacLeod, H., Mohrs, M., Brombacher, F., Bottomly, K., 1999. Th2-induced airway mucus production is dependent on IL-4R $\alpha$ , but not on eosinophils. *J. Immunol.* 162, 6178–6183.
- Grunig, G., Warnock, M., Wakil, A.E., Venkayya, R., Brombacher, F., Rennick, D.M., Sheppard, D., Mohrs, M., Donaldson, D.D., Locksley, R.M., Corry, D.B., 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. *Science* 282, 2261–2263.
- Heard, B.E., Hossain, S., 1973. Hyperplasia of bronchial muscle in asthma. *J. Pathol.* 110, 319–331.
- Holt, P.G., Batty, J.E., Turner, K.J., 1981. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. *Immunology* 42, 409–417.
- Huss, K., Adkinson Jr., N.F., Eggleston, P.A., Dawson, C., Van Natta, M.L., Hamilton, R.G., 2001. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. *J. Allergy Clin. Immunol.* 107, 48–54.
- Jeffery, P.K., Godfrey, R.W., Adelroth, E., Nelson, F., Rogers, A., Johansson, S.A., 1992. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. *Am. Rev. Respir. Dis.* 145, 890–899.
- Johnson, J.R., Wiley, R.E., Fattouh, R., Swirski, F.K., Gajewska, B.U., Coyle, A.J., Gutierrez-Ramos, J.C., Ellis, R., Inman, M.D., Jordana, M., 2004. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. *Am. J. Respir. Crit. Care Med.* 169, 378–385.
- King, T.P., Hoffman, D., Lowenstein, H., Marsh, D.G., Platts-Mills, T.A., Thomas, W., 1994. Allergen nomenclature. WHO/IUIS Allergen Nomenclature Subcommittee. *Int. Arch. Allergy Immunol.* 105, 224–233.
- Kips, J.C., Anderson, G.P., Fredberg, J.J., Herz, U., Inman, M.D., Jordana, M., Kemeny, D.M., Lotvall, J., Pauwels, R.A., Plopper, C.G., Schmidt, D., Sterk, P.J., Van Oosterhout, A.J., Vargaftig, B.B., Chung, K.F., 2003. Murine models of asthma. *Eur. Respir. J.* 22, 374–382.
- Komai, M., Tanaka, H., Masuda, T., Nagao, K., Ishizaki, M., Sawada, M., Nagai, H., 2003. Role of Th2 responses in the development of allergen-induced airway remodeling in a murine model of allergic asthma. *Br. J. Pharmacol.* 138, 912–920.
- Kuperman, D.A., Huang, X., Nguyenvu, L., Holscher, C., Brombacher, F., Erle, D.J., 2005. IL-4 receptor signaling in Clara cells is required for allergen-induced mucus production. *J. Immunol.* 175, 3746–3752.

- Louahed, J., Toda, M., Jen, J., Hamid, Q., Renaud, J.C., Levitt, R.C., Nicolaides, N.C., 2000. Interleukin-9 upregulates mucus expression in the airways. *Am. J. Respir. Cell Mol. Biol.* 22, 649–656.
- Lundgren, R., Soderberg, M., Horstedt, P., Stenling, R., 1988. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. *Eur. Respir. J.* 1, 883–889.
- Mannino, D.M., Homa, D.M., Akinbami, L.J., Moorman, J.E., Gwynn, C., Redd, S.C., 2002. Surveillance for asthma—United States, 1980–1999. *MMWR. Surveill. Summ.* 51, 1–13.
- Nagai, H., Maeda, Y., Tanaka, H., 1997. The effect of anti-IL-4 monoclonal antibody, rapamycin and interferon-gamma on airway hyperreactivity to acetylcholine in mice. *Clin. Exp. Allergy* 27, 218–224.
- Noben-Trauth, N., Shultz, L.D., Brombacher, F., Urban Jr., J.F., Gu, H., Paul, W.E., 1997. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. *Proc. Natl. Acad. Sci. U. S. A.* 94, 10838–10843.
- Noben-Trauth, N., Paul, W.E., Sacks, D.L., 1999. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to *Leishmania* major parasite substrains. *J. Immunol.* 162, 6132–6140.
- Ohkawara, Y., Lei, X.F., Stampfli, M.R., Marshall, J.S., Xing, Z., Jordana, M., 1997. Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation. *Am. J. Respir. Cell Mol. Biol.* 16, 510–520.
- Olivieri, D., Chetta, A., Del Donno, M., Bertorelli, G., Casalini, A., Pesci, A., Testi, R., Foresi, A., 1997. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. *Am. J. Respir. Crit. Care Med.* 155, 1864–1871.
- Pauluhn, J., Mohr, U., 2005. Experimental approaches to evaluate respiratory allergy in animal models. *Exp. Toxicol. Pathol.* 56, 203–234.
- Platts-Mills, T.A., Vervloet, D., Thomas, W.R., Aalberse, R.C., Chapman, M.D., 1997. Indoor allergens and asthma: report of the Third International Workshop. *J. Allergy Clin. Immunol.* 100, S2–S24.
- Redington, A.E., Madden, J., Frew, A.J., Djukanovic, R., Roche, W.R., Holgate, S.T., Howarth, P.H., 1997. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. *Am. J. Respir. Crit. Care Med.* 156, 642–647.
- Robertson, C.F., Roberts, M.F., Kappers, J.H., 2004. Asthma prevalence in Melbourne schoolchildren: have we reached the peak? *Med. J. Aust.* 180, 273–276.
- Robinson, D.S., Hamid, Q., Ying, S., Tscipoulos, A., Barkans, J., Bentley, A.M., Corrigan, C., Durham, S.R., Kay, A.B., 1992. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. *N. Engl. J. Med.* 326, 298–304.
- Roche, W.R., Beasley, R., Williams, J.H., Holgate, S.T., 1989. Subepithelial fibrosis in the bronchi of asthmatics. *Lancet* 1, 520–524.
- Sadakane, K., Ichinose, T., Takano, H., Yanagisawa, R., Sagai, M., Yoshikawa, T., Shibamoto, T., 2002. Murine strain differences in airway inflammation induced by diesel exhaust particles and house dust mite allergen. *Int. Arch. Allergy Immunol.* 128, 220–228.
- Sacta, M., Di Stefano, A., Rosina, C., Thiene, G., Fabbri, L.M., 1991. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. *Am. Rev. Respir. Dis.* 143, 138–143.
- Sakai, K., Yokoyama, A., Kohno, N., Hamada, H., Hiwada, K., 2001. Prolonged antigen exposure ameliorates airway inflammation but not remodeling in a mouse model of bronchial asthma. *Int. Arch. Allergy Immunol.* 126, 126–134.
- Sont, J.K., Willems, L.N., Bel, E.H., van Kricken, J.H., Vandembroucke, J.P., Sterk, P.J., 1999. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. *Am. J. Respir. Crit. Care Med.* 159, 1043–1051.
- Sporik, R., Holgate, S.T., Platts-Mills, T.A., Cogswell, J.J., 1990. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. *N. Engl. J. Med.* 323, 502–507.
- Swirski, F.K., Gajewska, B.U., Alvarez, D., Ritz, S.A., Cundall, M.J., Cates, E.C., Coyle, A.J., Gutierrez-Ramos, J.C., Inman, M.D., Jordana, M., Stampfli, M.R., 2002. Inhalation of a harmless antigen (ovalbumin) elicits immune activation but divergent immunoglobulin and cytokine activities in mice. *Clin. Exp. Allergy* 32, 411–421.
- Tanaka, H., Masuda, T., Tokuoka, S., Komai, M., Nagao, K., Takahashi, Y., Nagai, H., 2001. The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. *Inflamm. Res.* 50, 616–624.
- Tanaka, H., Komai, M., Nagao, K., Ishizaki, M., Kajiwara, D., Takatsu, K., Delespesse, G., Nagai, H., 2004. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. *Am. J. Respir. Cell Mol. Biol.* 31, 62–68.
- Temann, U.A., Prasad, B., Gallup, M.W., Basbaum, C., Ho, S.B., Flavell, R.A., Rankin, J.A., 1997. A novel role for murine IL-4 in vivo: induction of MUC5AC gene expression and mucin hypersecretion. *Am. J. Respir. Cell Mol. Biol.* 16, 471–478.
- Tomkinson, A., Duez, C., Cieslewicz, G., Pratt, J.C., Joctham, A., Shanafelt, M.C., Gundel, R., Gelfand, E.W., 2001. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. *J. Immunol.* 166, 5792–5800.
- van Essen-Zandvliet, E.E., Hughes, M.D., Waalkens, H.J., Duiverman, E.J., Pooock, S.J., Kerrebijn, K.F., 1992. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. *Am. Rev. Respir. Dis.* 146, 547–554.
- Vanacker, N.J., Palmans, E., Pauwels, R.A., Kips, J.C., 2002. Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats. *Eur. Respir. J.* 20, 873–879.
- Verlato, G., Corsico, A., Villani, S., Cerveri, I., Migliore, E., Accordini, S., Carolei, A., Piccioni, P., Bugiani, M., Lo Cascio, V., Marinoni, A., Poli, A., de Marco, R., 2003. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. *J. Allergy Clin. Immunol.* 111, 1232–1238.
- Vignola, A.M., Chanec, P., Chiappara, G., Merendino, A., Pace, E., Rizzo, A., la Rocca, A.M., Bellia, V., Bonsignore, G., Bousquet, J., 1997. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. *Am. J. Respir. Crit. Care Med.* 156, 591–599.
- Wills-Karp, M., 2000. Murine models of asthma in understanding immune dysregulation in human asthma. *Immunopharmacology* 48, 263–268.
- Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T.Y., Karp, C.L., Donaldson, D.D., 1998. Interleukin-13: central mediator of allergic asthma. *Science* 282, 2258–2261.
- Yu, C.K., Shieh, C.M., Lei, H.Y., 1999. Repeated intratracheal inoculation of house dust mite (*Dermatophagoides farinae*) induces pulmonary eosinophilic inflammation and IgE antibody production in mice. *J. Allergy Clin. Immunol.* 104, 228–236.



## Letters to the Editor

### Genetic polymorphism regulating ORM1-like 3 (*Saccharomyces cerevisiae*) expression is associated with childhood atopic asthma in a Japanese population

To the Editor:

Bronchial asthma is a complex disease caused by a combination of genetic and environmental factors.<sup>1</sup> A recent study using genome-wide association analysis has shown that single nucleotide polymorphisms (SNPs) on the chromosome 17q21.1 locus contribute to the risk of childhood asthma.<sup>2</sup> Genetic variants of the region were strongly associated in *cis* with transcript levels of *ORM1-like 3* (*S cerevisiae*; *ORMDL3*) in EBV-transformed lymphoblastoid cell lines from children with asthma.<sup>2</sup> The *ORMDL3* transcripts were strongly and positively associated with the SNPs ( $P < 10^{-22}$  for rs7216389) in the disease-associated locus, and rs7216389 was the marker most strongly associated with the disease in combined genome-wide association analysis.<sup>2</sup> *ORMDL3* is a member of a gene family that encodes transmembrane proteins anchored in the endoplasmic reticulum; however, the gene function is unclear.<sup>3</sup> It was reported that *ORMDL3* was expressed in many tissues, particularly in liver and peripheral blood lymphocytes.<sup>2</sup> In the induction of asthma, the important role of respiratory tract infections has been recognized.<sup>4,5</sup> Clinical studies suggest that the proportion of virus-induced asthma exacerbations is likely to be around 80% to 85% in school-age children.<sup>6</sup> To assess whether the genetic variations regulating *ORMDL3* expression contribute to the susceptibility in childhood atopic asthma in a Japanese population, we conducted association studies using the marker rs7216389. A total of 545 children with atopic asthma were recruited, and all subjects with asthma were diagnosed according to the criteria of the National Institutes of Health (mean age, 9.5, 3.6-17 years; male:female ratio, 1.49:1.0).<sup>7</sup> The mean  $\log_{10}$ (total IgE [IU/mL]) of patients was 2.75. A total of 738 healthy subjects who had neither respiratory symptoms nor a history of asthma-related diseases (mean age, 49, 19-78 years; male:female ratio, 2.68:1.0) were recruited after being interviewed by physicians regarding whether they had been diagnosed with asthma, atopic dermatitis, or nasal allergies. The profiles of patients with asthma and controls were provided in our recent report.<sup>8,9</sup> All individuals were unrelated Japanese and gave written informed consent to participate in the study according to the rules of the process committee at the Institute of Physical and Chemical Research. Genotyping of the SNP was performed by the TaqMan allele-specific amplification (TaqMan-ASA) method (Applied Biosystems, Foster City, Calif). rs7216389 was genotyped by using TaqMan(R) Pre-Designed SNP Genotyping Assays, C\_29062108\_10. We calculated allele frequencies and tested agreement with Hardy-Weinberg equilibrium using a  $\chi^2$  goodness-of-fit test. We then compared differences in the allele frequencies and genotype distribution of the polymorphism between case and control subjects by using a contingency  $\chi^2$  test and calculated odds ratios (ORs) with 95% CIs. All genotype frequencies are shown in Table I. We found a significant association between the rs7216389 genotype and children with atopic asthma (T allele vs C allele frequency, OR, 1.44; 95% CI, 1.20-1.73;  $\chi^2 = 15.6$ ;  $P = .000080$ ;

TABLE I. Genotype frequencies for rs7216389 and childhood atopic asthma susceptibility

Genotype	Cases (%) (n = 545)	Controls (%) (n = 738)	P value OR (95% CI)			
			TT vs TC vs CC	TT vs TC + CC	TT + TC vs CC	T allele vs C allele
TT	338 (62.0)	370 (50.1)	.00013	.000023	.181	.000080
TC	176 (32.3)	312 (42.3)		1.62		1.44
CC	31 (5.7)	56 (7.6)		(1.30-2.03)		(1.20-1.73)
T	852 (78.2)	1052 (71.3)				
C	238 (21.8)	424 (28.7)				




FIG 1. Induction of *ORMDL3* expression in NHLF in response to poly(I:C). Quantitative RT-PCR assay of *ORMDL3*. Normal human bronchial epithelial cells, NHLF, and bronchial smooth muscle cells were stimulated with 10  $\mu$ g/mL poly(I:C), 100 ng/mL LPS, 1  $\mu$ g/mL macrophage-activating lipopeptide 2 (MALP-2), or 200 ng/mL Pam3CSK4 for 24 hours. We used the following primer sets for RT-PCR: 5'-AAGGCGAGGCTGCTAAC-3' and 5'-TGTA GAAGCTGGTGAGGAAGTACA-3'. Data represent means  $\pm$  SDs of triplicate samples. mRNA expression analysis was performed with the Student t test. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.

TT vs TC+CC, OR, 1.62; 95% CI, 1.30-2.03;  $\chi^2 = 17.9$ ;  $P = .000023$ ; Table I). In our study, the T nucleotide allele at rs7216389 had a frequency of 78% among subjects with asthma compared with 71% in subjects without asthma, and the direction of association was similar to findings in a previous study.<sup>2</sup> Serum total IgE levels were analyzed as quantitative levels, and we investigated associations between these levels and genetic variation within patients with childhood asthma. Multiple comparisons were first analyzed by the Kruskal-Wallis test, and correlations were analyzed by the Spearman test. However, we could not find any association between the genetic variant and serum IgE levels of patients with asthma in this study. We next assessed whether the *ORMDL3* could be induced in lung-derived cells by some pathogen-associated microbial patterns recognized by Toll-like receptors and other pattern-recognition receptors as described.<sup>10</sup> We investigated the *ORMDL3* expression in lung-derived primary cells, including normal human bronchial epithelial cells, normal human lung fibroblasts (NHLF), and normal human bronchial smooth muscle cells (Fig 1). In NHLF, the expression level of *ORMDL3* was strongly induced for 24 hours by stimulation with polyinosine-polycytidylic acid but not by LPS, macrophage-activating lipopeptide 2, or Pam3CSK4 (Fig 1). These results implied that the high induction of *ORMDL3* in lung fibroblasts might play a role in viral respiratory infections.

We found a significant association between susceptibility to childhood atopic asthma and the polymorphism regulating *ORMDL3* expression in a Japanese population. Our data strongly support the important role of *ORMDL3* in childhood asthma. Further investigation of the functional role of the variant during allergic events may provide additional targets for therapeutic interventions and would be helpful to clarify the etiology of childhood asthma.

Tomomitsu Hirota, DDS, PhD<sup>a</sup>  
 Michishige Harada, PhD<sup>a</sup>  
 Masafumi Sakashita, MD<sup>a</sup>  
 Satoru Doi, MD, PhD<sup>b</sup>  
 Akihiko Miyatake, MD, PhD<sup>c</sup>  
 Kimie Fujita, MD, PhD<sup>d</sup>  
 Tadao Enomoto, MD, PhD<sup>d</sup>  
 Motohiro Ebisawa, MD, PhD<sup>e</sup>  
 Shigemi Yoshihara, MD, PhD<sup>f</sup>  
 Emiko Noguchi, MD, PhD<sup>g</sup>  
 Hirohisa Saito, MD, PhD<sup>h</sup>  
 Yusuke Nakamura, MD, PhD<sup>i</sup>  
 Mayumi Tamari, MD, PhD<sup>a</sup>

From <sup>a</sup>the Laboratory for Genetics of Allergic Diseases, SNP Research Center, Institute of Physical and Chemical Research, Yokohama, Japan; <sup>b</sup>the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan; <sup>c</sup>Miyatake Asthma Clinic, Osaka, Japan; <sup>d</sup>the Japanese Red Cross Society, Wakayama Medical Center, Wakayama, Japan; <sup>e</sup>National Sagami Hospital, Sagami, Japan; <sup>f</sup>Dokkyo University School of Medicine, Tochigi, Japan; <sup>g</sup>the Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; <sup>h</sup>the National Research Institute for Child Health and Development, Tokyo, Japan; <sup>i</sup>the Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. E-mail: tamari@src.riken.jp.

Supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labor and Welfare of Japan.

Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

## REFERENCES

- Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. *Nat Rev Immunol* 2004;4:978-88.
- Moffatt MF, Kabisch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating *ORMDL3* expression contribute to the risk of childhood asthma. *Nature* 2007;448:470-3.
- Hjeltnqvist L, Tuson M, Marfany G, Herrero E, Balcells S, Gonzalez-Duarte R. *ORMDL* proteins are a conserved new family of endoplasmic reticulum membrane proteins. *Genome Biol* 2002;3:research0027.1-research0027.16.
- Contoli M, Caramori G, Mallia P, Johnston S, Papi A. Mechanisms of respiratory virus-induced asthma exacerbations. *Clin Exp Allergy* 2005;35:137-45.
- Pattemore PK. Respiratory infections in allergy and asthma. In: Johnston SL, Papadopoulos NG, editors. *Epidemiology and diagnosis of virus-induced asthma exacerbations*. New York: Informa Healthcare; 2003. p. 43-89.
- Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995;310:1225-9.
- National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. National Asthma Education Program, Expert Panel Report. *J Allergy Clin Immunol* 1991;88:425-534.
- Hirota T, Suzuki Y, Hasegawa K, Obara K, Matsuda A, Akahoshi M, et al. Functional haplotypes of IL-12B are associated with childhood atopic asthma. *J Allergy Clin Immunol* 2005;116:789-95.
- Hatsushika K, Hirota T, Harada M, Sakashita M, Kanzaki M, Takano S, et al. Transforming growth factor-beta(2) polymorphisms are associated with childhood atopic asthma. *Clin Exp Allergy* 2007;37:1165-74.
- Nakashima K, Hirota T, Obara K, Shimizu M, Doi S, Fujita K, et al. A functional polymorphism in MMP-9 is associated with childhood atopic asthma. *Biochem Biophys Res Commun* 2006;344:300-7.

## How readable are the American Academy of Allergy, Asthma & Immunology "Tips to Remember" leaflets?

To the Editor:

It has long been recognized that good communication has a beneficial effect on clinical outcomes,<sup>1</sup> and patient information leaflets can improve knowledge.<sup>2</sup> However, the information must not only be accurate but also written at an appropriate reading level to be helpful. National literacy surveys conducted since the 1970s have consistently shown that many adult Americans (about 20%) are functionally illiterate and that the average adult reading level is between the seventh and ninth grade levels.<sup>3,4</sup>

The American Academy of Allergy, Asthma & Immunology (AAAAI) "Tips to Remember" leaflets cover a wide range of topics for patients with asthma and allergic diseases, including diagnostic tests and the use of medication. To predict the level of educational attainment needed to understand and benefit from these, we analyzed the readability of the 29 English-language brochures by using the Simple Measure of Gobbledegook (SMOG).<sup>5</sup> This formula was selected because it is simple, quick, and widely used and has been shown to be reliable and valid in determining reading level.<sup>6</sup> The SMOG formula yields a high correlation (0.985) with the grades of readers who had 100% comprehension of the set material. A score of 8 equates with completion of junior high school. Completed high school is needed for reading material with a score of 12, and tertiary education is required for a score of 13 and above (Table I). Texts with a SMOG score of less than 5 will be understood by most persons, and it has therefore been recommended that health literature should ideally be written at a SMOG score of 5 or less.<sup>7</sup>

To obtain a SMOG score, 30 sentences were selected (10 from the start, 10 from the middle, and 10 from the end of the brochure) and pasted into the SMOG Calculator (<http://www.wordcount.info>). We found that the "Tips to Remember" brochures have SMOG scores ranging from 12.27 to 16.78 (ie, requiring successful completion of education between high school graduation and university degree; Table I). For comparison, we scored the readability of 6 editorial and review articles from the *Journal of Allergy and Clinical Immunology*. We randomly selected one article from volumes 113 to 118. Original research articles were excluded, so that the text was relatively free of abbreviations, gene sequences, or numeric data. These editorials and reviews had SMOG scores of between 15.37 and 17.46 (mean, 16.55; Table I).

Sometimes methods based on word length are criticized because they disregard patients' familiarity with the vocabulary that is associated with their illness, thereby overestimating the difficulty of the text. Because the word *allergy* and its many derivatives are polysyllabic, we assessed whether complexity of the text was reduced if familiar words such as *allergy*, *allergies*, *allergist(s)*, *allergic*, *allergenic*, and *allergen(s)* were excluded from the scoring. These exclusions had very little effect on the readability of the brochures. For example, the brochure showing the greatest shift in score ("What are allergy shots?") decreased from 15.08 to 13.20 after removing these words (Table II). We then went on to exclude from the scoring all the polysyllabic medical and technical terms defined within each brochure. The readability scores improved further, but the magnitude of shift makes very little

# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Early-Life Risk Factors for Occurrence of Atopic Dermatitis During the First Year**

Mikio Sugiyama, Hirokazu Arakawa, Kiyoshi Ozawa, Takahisa Mizuno, Hiroyuki Mochizuki, Kenichi Tokuyama and Akihiro Morikawa

*Pediatrics* 2007;119:e716-e723

DOI: 10.1542/peds.2006-0893

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://www.pediatrics.org/cgi/content/full/119/3/e716>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2007 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



## Early-Life Risk Factors for Occurrence of Atopic Dermatitis During the First Year

Mikio Sugiyama, MD<sup>a</sup>, Hirokazu Arakawa, MD, PhD<sup>a</sup>, Kiyoshi Ozawa, MD, PhD<sup>b</sup>, Takahisa Mizuno, MD<sup>a</sup>, Hiroyuki Mochizuki, MD, PhD<sup>a</sup>, Kenichi Tokuyama, MD, PhD<sup>a</sup>, Akihiro Morikawa, MD, PhD<sup>a</sup>

<sup>a</sup>Department of Pediatrics and Developmental Medicine, Gunma University Graduate School of Medicine, Gunma, Japan; <sup>b</sup>Ozawa Obstetric Clinic, Gunma, Japan

The authors have indicated they have no financial relationships relevant to this article to disclose.

### ABSTRACT

**OBJECTIVE.** In a prospective birth cohort study, we sought to identify perinatal predictors of the occurrence of atopic dermatitis in the first year of life.

**METHODS.** Associations of family history, infection during pregnancy, cord blood cytokine concentrations, and skin function parameters with atopic dermatitis were analyzed. Stratum corneum hydration was measured with an impedance meter until 5 days after delivery and again at 1 month.

**RESULTS.** Complete data were obtained for 213 infants, including 27 diagnosed by a physician as having atopic dermatitis during their first year and 26 diagnosed as having infantile eczema during their first month. The risk of atopic dermatitis during the first year of life was related to maternal atopic dermatitis, lower concentrations of macrophage inflammatory protein-1 $\beta$  in cord blood, and greater skin moisture in the surface and stratum corneum of the forehead and cheek at 1 month of age but not to viral or bacterial infection during pregnancy or breastfeeding. Paternal hay fever was associated negatively with the development of atopic dermatitis. High concentrations of interleukin-5, interleukin-17, and macrophage chemotactic protein-1 and only surface moisture in the cheek were associated with greater risk of infantile eczema in the first month.

**CONCLUSIONS.** The association of atopic dermatitis in infancy with reduced neonatal macrophage inflammatory protein-1 $\beta$  levels suggests a link with immature immune responses at birth. Stratum corneum barrier disruption in atopic dermatitis may involve impairment of cutaneous adaptation to extrauterine life. The majority of risk factors had different effects on infant eczema and atopic dermatitis, indicating different causes.

[www.pediatrics.org/cgi/doi/10.1542/peds.2006-0893](http://www.pediatrics.org/cgi/doi/10.1542/peds.2006-0893)

doi:10.1542/peds.2006-0893

#### Key Words

atopic dermatitis, skin physiology, cytokine, chemokine, infantile eczema

#### Abbreviations

AD—atopic dermatitis

IL—interleukin

TNF—tumor necrosis factor

IFN—interferon

MCP—monocyte chemotactic protein

MIP—macrophage inflammatory protein

OR—odds ratio

CI—confidence interval

Th—T helper

Accepted for publication Sep 22, 2006

Address correspondence to Hirokazu Arakawa, MD, PhD, Department of Pediatrics and Developmental Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. E-mail: [harakawa@showa.gunma-u.ac.jp](mailto:harakawa@showa.gunma-u.ac.jp)

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2007 by the American Academy of Pediatrics